Boehringer In­gel­heim inks deal for tar­get­ed can­cer an­ti­bod­ies from Sin­ga­pore re­search org

As Boehringer In­gel­heim looks to build out its ef­forts in on­col­o­gy, its lat­est deal will turn to­ward Sin­ga­pore.

The Ger­man phar­ma an­nounced Thurs­day that it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER